CymaBay shares get a bounce on positive PBC PhII data
CymaBay Therapeutics got a badly needed boost this morning after its lead drug scored some positive data in a Phase II trial.
The Newark, CA-based biotech — the old Metabolex, which has had its share of ups and downs over the years — says two doses of saledelpar demonstrated an ability to slash levels of alkaline phosphatase among treatment-resistant patients suffering from primary biliary cholangitis. The 5 mg and 10 mg doses cut AP levels by 39% and 45% from baseline after 12 weeks of therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
